Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 10/2023

Open Access 23-09-2023 | Vulgar Psoriasis | Review

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review

Authors: Tiago Torres, Jordi Galván, Nigel Crutchley, Morten Praestegaard, Lars Iversen, Paolo Gisondi, José Manuel Carrascosa, Bruno Halioua, Anthony Bewley, Andreas Pinter

Published in: Dermatology and Therapy | Issue 10/2023

Login to get access

Abstract

Topical treatment plays a crucial role in psoriasis management, with non-adherence being a major barrier to treatment success. The fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) represents the first-line choice in topical psoriasis treatment. A CAL/BDP cream based on polyaphron dispersion (PAD) Technology has emerged as a novel formulation for a more convenient topical treatment of psoriasis. This article aims to summarize the most relevant published evidence about CAL/BDP PAD-cream and its underlying PAD Technology. The PAD Technology enables CAL and BDP stability in an aqueous cream through a multimolecular shell structure, as well as it increases the penetration of both active ingredients into the epidermis and dermis. This technology also demonstrated to increase the cosmetic acceptability and to provide the desirable sensory properties for a topical psoriasis treatment. Two phase III clinical trials have been conducted so far with CAL/BDP PAD-cream. Findings from both trials revealed high efficacy with a fast onset of action, a favourable safety and tolerability profile and convenience for CAL/BDP PAD-cream compared to CAL/BDP gel. In the trial including patients with psoriasis affecting the scalp (MC2-01-C7), results support the use of CAL/BDP PAD-cream in scalp psoriasis. An anchored matching-adjusted indirect comparison (MAIC) was conducted to compare CAL/BDP PAD-cream and CAL/BDP foam, as both products had been previously compared to CAL/BDP gel. CAL/BDP PAD-cream and CAL/BDP foam showed equivalent efficacy and quality of life at their recommended treatment duration, whereas greater treatment satisfaction for CAL/BDP PAD-cream was found after one week of treatment. Overall, the high patient acceptability and treatment satisfaction observed with CAL/BDP PAD-cream in clinical trials may lead to improved adherence and hence higher efficacy in clinical practice.
Literature
1.
Pinter A, van de Kerkhof P. The role of topical therapies along the psoriasis patient journey: an overview from the Symposium “Tailoring topical psoriasis treatments to patients” needs and expectations’ of the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023;37(Suppl 1):3–8.CrossRefPubMed
2.
Chat VS, Kearns DG, Uppal SK, Han G, Wu JJ. Management of psoriasis with topicals: applying the 2020 AAD-NPF guidelines of care to clinical practice. Cutis. 2022;110(2 Suppl):8–14.CrossRefPubMed
3.
Le Roux E, Frow H. Diagnosis and management of mild to moderate psoriasis. Prescriber. 2020;31(7–8):9–17.CrossRef
4.
5.
6.
7.
Puig L, Carrascosa JM, Belinchón I, Fernández-Redondo V, Carretero G, Ruiz-Carrascosa JC, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104(6):488–96.CrossRefPubMed
8.
Vasconcelos V, Teixeira A, Almeida V, Teixeira M, Ramos S, Torres T, et al. Patient preferences for attributes of topical anti-psoriatic medicines. J Dermatolog Treat. 2019;30(7):659–63.CrossRefPubMed
9.
Pinter A, Gold LS, Reich A, Green LJ, Praestegaard M, Selmer J, et al. A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023;37(Suppl 1):14–9.CrossRefPubMed
10.
Segaert S, Shear NH, Chiricozzi A, Thaçi D, Carrascosa JM, Young H, et al. Optimizing anti-inflammatory and immunomodulatory effects of corticosteroid and vitamin D analogue fixed-dose combination therapy. Dermatol Ther (Heidelb). 2017;7(3):265–79.CrossRefPubMed
11.
Megna M, Cinelli E, Camela E, Fabbrocini G. Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data. Expert Rev Clin Immunol. 2020;16(6):599–620.CrossRefPubMed
12.
Praestegaard M, Steele F, Crutchley N. Polyaphron dispersion technology, a novel topical formulation and delivery system combining drug penetration, local tolerability and convenience of application. Dermatol Ther (Heidelb). 2022;12(10):2217–31.CrossRefPubMed
13.
García N, Guiró P, Galván J, Crutchley N, Praestegaard M, Iversen L, et al. Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD Technology for the treatment of plaque psoriasis on the skin and scalp. Drugs Context. 2023;12:1–8.CrossRef
14.
15.
Draelos ZD, Draelos MM, Steele F, Georgiou M, Praestegaard M. Enhanced skin deposition of betamethasone dipropionate from a novel formulation and drug delivery technology. Dermatol Ther (Heidelb). 2023;13(8):1763–1771. CrossRef
16.
Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36(2):228–36.CrossRefPubMed
17.
18.
19.
Pinter A, Iversen L, Praestegaard M, Stein Gold L. Fixed dose calcipotriene (CAL) and betamethasone dipropionate (BDP) cream significantly improves plaque psoriasis at week one in a pooled analysis of phase 3 data. Poster presented at the 31st EADV Congress 2022, 7–10 September (Milan, Italy). Abstract ID: 1738.
20.
Pinter A, Praestegaard M, Selmer J, Reich A. Efficacy of calcipotriene and betamethasone dipropionate cream based on PAD Technology in patients with scalp psoriasis. Poster presented at the 31st EADV Congress 2022, 7–10 September (Milan, Italy). Poster number: P1528.
21.
Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20(4):420–5.CrossRefPubMed
22.
Armstrong A, Pinter A, Selmer J, Præstegaard M, Reich A, Koo J. Pooled analysis demonstrating superior patient- reported psoriasis treatment outcomes for calcipotriene/betamethasone dipropionate cream versus suspension/gel. J Drugs Dermatol. 2022;21(3):242–8.PubMed
23.
Halioua B, Bewley A, Snel-Prentø A. Dans le traitement du psoriasis en plaques, la crème CAL/BDP a montré moins d’interférences avec le choix vestimentaire et d’autres activités quotidiennes du patient par rapport au gel CAL/BDP:analyse groupée de 2 essais de phase 3, randomisés, contrôlés. Poster presented at the JDP Congress 2022, 29 November–03 December.
24.
Bewley A, Barker E, Baker H, Green W, Avey B, Pi-Blanque A, et al. An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis. J Dermatolog Treat. 2022;33(8):3191–8.CrossRefPubMed
25.
Kircik C, Kircik L. Patient preference for calcipotriene and betamethasone dipropionate cream versus foam for the topical treatment of psoriasis: a pilot study. J Drugs Dermatol. 2023;22(3):271–3.CrossRefPubMed
26.
Bewley A, van de Kerkhof P. Engaging psoriasis patients in adherence and outcomes to topical treatments: a summary from the Symposium “Tailoring topical psoriasis treatments to patients” needs and expectations’ of the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023;37(Suppl 1):9–13.CrossRefPubMed
27.
Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, et al. Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. J Eur Acad Dermatol Venereol. 2017;31(8):1271–84.CrossRefPubMed
28.
Svendsen MT, Feldman SR, Tiedemann SN, Sørensen ASS, Rivas CMR, Andersen KE. Psoriasis patient preferences for topical drugs: a systematic review. J Dermatolog Treat. 2021;32(5):478–83.CrossRefPubMed
Metadata
Title
Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
Authors
Tiago Torres
Jordi Galván
Nigel Crutchley
Morten Praestegaard
Lars Iversen
Paolo Gisondi
José Manuel Carrascosa
Bruno Halioua
Anthony Bewley
Andreas Pinter
Publication date
23-09-2023
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 10/2023
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-023-01003-0

Other articles of this Issue 10/2023

Dermatology and Therapy 10/2023 Go to the issue

Original Research

Circadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical Study

Original Research

Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study

Original Research

Natural Retinol Analogs Potentiate the Effects of Retinal on Aged and Photodamaged Skin: Results from In Vitro to Clinical Studies

Case Report

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab

Original Research

Dermoscopy as a Noninvasive Diagnostic Tool for Hailey-Hailey Disease and Darier Disease

Original Research

Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits